Terms: = Ovarian cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Prognosis
3 results:
1. Dual inhibition of cdk12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract] [Full Text] [Related]
2. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Guffanti F; Fruscio R; Rulli E; Damia G
Sci Rep; 2016 Dec; 6():38142. PubMed ID: 27905519
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Characterization of High-Grade Serous ovarian cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract] [Full Text] [Related]
